Richmond, BC (pcJ News Briefs) – Liberty Biopharma Inc. (TSX-V: LTY) has obtained a receipt for a preliminary short form prospectus in connection with a proposed offering of units for gross proceeds of up to $10 million. The offering will be conducted on a “best efforts” basis with Kernaghan & Partners Ltd. acting as agent.
Liberty Biopharma intends to use the net proceeds for ongoing expansion and execution of worldwide sales and marketing plans, strategic acquisitions, general purposes, working capital and reserve.
Liberty Biopharma is a clinical stage biopharmaceutical company developing and commercializing regenerative stem cell technologies and therapeutic solutions for independence and quality of life. Its focus is on significant areas of unmet clinical need, such as wound management, osteoarthritis, musculoskeletal injury, cardiovascular diseases, and autoimmune diseases.
photo credit: Liberty Biopharma